Research Analysts Issue Forecasts for INBX Q3 Earnings

Key Points

• HC Wainwright forecasts a Q3 2026 loss of $2.14 per share for Inhibrx Biosciences and maintains a Buy rating with a $245 price target.
• The company reported a Q2 loss of $2.34 per share, missing the $2.28 consensus estimate by $0.06. HC Wainwright expects full-year losses of $8.93 per share in 2026 and $8.47 in 2027, indicating improving but still negative earnings.
• Analyst sentiment is mixed but leans positive, with an overall “Moderate Buy” consensus and an average price target of $197.50; institutional investors own 82.46% of the stock.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) - Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Inhibrx Biosciences in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($2.14) for the quarter. HC Wainwright currently has a "Buy" rating and a $245.00 target price on the stock. The consensus estimate for Inhibrx Biosciences' current full-year earnings is ($10.88) per share. HC Wainwright also issued estimates for Inhibrx Biosciences' Q4 2026 earnings at ($2.30) EPS, FY2026 earnings at ($8.93) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.15) EPS, Q3 2027 earnings at ($2.08) EPS, Q4 2027 earnings at ($2.02) EPS and FY2027 earnings at ($8.47) EPS.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing the consensus estimate of ($2.28) by ($0.06).

INBX has been the topic of a number of other reports. Wall Street Zen lowered shares of Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a research report on Monday, August 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inhibrx Biosciences in a report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $197.50.

Inhibrx Biosciences Price Performance

Inhibrx Biosciences stock opened at $122.72 on Wednesday. The company has a fifty day simple moving average of $92.45 and a 200-day simple moving average of $89.81. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -13.82 and a beta of 3.51. The company has a quick ratio of 5.07, a current ratio of 5.07 and a debt-to-equity ratio of 12.58. Inhibrx Biosciences has a 52-week low of $24.27 and a 52-week high of $155.29.

Institutional Investors Weigh In On Inhibrx Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd acquired a new position in shares of Inhibrx Biosciences in the 4th quarter valued at $27,000. Strs Ohio acquired a new stake in shares of Inhibrx Biosciences during the 1st quarter worth about $27,000. Public Employees Retirement System of Ohio purchased a new stake in Inhibrx Biosciences in the 3rd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Inhibrx Biosciences by 26.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company's stock valued at $56,000 after buying an additional 147 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company's stock valued at $64,000 after buying an additional 789 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Biosciences News Summary

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $245 price target, implying approximately 99.6% upside from the referenced $122.72 price. The bullish target appears to be the primary catalyst supporting the stock’s increase. HC Wainwright Begins Coverage on Inhibrx Biosciences
• Positive Sentiment: HC Wainwright projects 2026 EPS of -$8.93 and 2027 EPS of -$8.47, both less negative than the current full-year consensus estimate of -$10.88. The forecasts suggest expectations for reduced losses over time, although the company remains unprofitable.
• Neutral Sentiment: The firm estimates quarterly losses of $2.14 per share in Q3 2026 and $2.30 in Q4 2026, followed by $2.22, $2.15, $2.08 and $2.02 in the four quarters of 2027. These projections provide a forward earnings framework but do not indicate near-term profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 25, unchanged from the prior reported period. This indicates no meaningful short-selling pressure in the available data, though the figure may reflect incomplete or anomalous reporting.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company's proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company's lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source